Seattle-based Parse Biosciences secured another major legal victory in its patent dispute with 10x Genomics Inc. (Nasdaq: TXG ...

Parse Biosciences, a leader in accessible and scalable single cell sequencing solutions, today ...

On, January 27, 2025, the United States Court of Appeals for the Federal Circuit affirmed-in-part and reversed-in-part a decision from the ...

The US Patent and Trademark Office told a group of specialized patent judges on Tuesday afternoon they could be expected to ...

In a significant ruling Monday, a Federal Circuit panel upheld two Patent Trial and Appeal Board (PTAB) decisions that invalidated claims in two patents held by USAA, one of which underpinned a ...

On January 27, in Apple Inc. v. Gesture Technology Partners, LLC, the Federal Circuit held that the Patent Trial and Appeal ...

If Trump’s prior presidential term serves as any indication of what is to come, we can expect to see several significant ...

This week we speak with Scott McKeown, who is a shareholder at Wolf Greenfield and one of the leading U.S. PTAB practitioners ...

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.

SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...

Atossa is also announcing the issuance of a new patent on January 21, 2025, U.S. Patent No. 12,201,591, entitled, “Sustained Release Compositions of Endoxifen.” The 31 claims of this new patent are ...

Atossa Therapeutics (ATOS) issued the following statement in response to the Patent Trial and Appeal Board’s, PTAB, final written decision in ...